



National Library of Medicine

National Center for Biotechnology Information

Record 1 of 1



U.S. government does not review or approve the safety and science of all studies listed on this website.

Read our full [disclaimer](https://clinicaltrials.gov/about-site/disclaimer) (https://clinicaltrials.gov/about-site/disclaimer) for details.

Completed

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

ClinicalTrials.gov ID NCT01409135

Sponsor Astellas Pharma Inc

Information provided by Astellas Pharma Inc (Responsible Party)

Last Update Posted 2024-03-12

Study Details Tab

Study Overview

Brief Summary

A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.

Detailed Description

AGS-22M6E and ASG-22CE are fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting Nectin-4 (Agensys code name AGS-22). The main difference between AGS-22M6E and ASG-22CE is the change in cell line for antibody production. AGS-22M6E and ASG-22CE will be administered at mg/kg doses based on the subjects weight at baseline and doses will not change unless the subjects weight changes by $\geq 10\%$ from their baseline weight or the investigational product Dosage Assessment criteria is met.

Subjects will be prescreened for Nectin-4 expression prior to undergoing screening procedures for the main study. Subjects with tumors positive for Nectin-4 expression may be screened for eligibility

Study Start (Actual) ⓘ

2011-07-11

Primary Completion (Actual) ⓘ

2015-04-27

Study Completion (Actual) ⓘ

2015-04-27

Enrollment (Actual) ⓘ

34

Study Type ⓘ

Interventional

Phase ⓘ

Phase 1

into the main study. The dose escalation period is estimated to take between 12 and 18 months depending on whether 3 or 6 subjects are enrolled in a given dose cohort, and the availability of consenting subjects.

Subjects will be treated in the dose escalation phase of the study until the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) has been determined by the data review team (DRT). After the RDE has been determined, subjects will be enrolled into 1 of 3 expansion cohorts. There will be 3 expansion cohorts, each targeting a specific cancer (i.e., Breast, Bladder and Lung plus other solid tumor cancers). The DRT may recommend stopping the study, adjusting the dose or amending the trial at any time.

The clinical bridging to the ASG-22CE involves treating the subjects with ASG-22CE, irrespective of cancer type, at the next lowest dose level previously determined to be safe for ASG-22M6E. After the initial subjects are treated at the bridging dose with ASG-22CE and have completed the safety assessment, future subjects will only be treated with ASG-22CE throughout the remainder of the study.

A disease assessment will be performed by the investigator at Week 8 (\pm 14 days). Subjects without evidence of disease

progression may continue to receive treatment until disease progression or intolerability.

Official Title

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4

Conditions

Tumors

Medical Oncology

Neoplasms

Intervention / Treatment

- Drug: AGS-22M6E
- Drug: ASG-22CE

Other Study ID Numbers

- AGS-22M6E-11-1

Resource links provided by the National Library of Medicine 

[MedlinePlus](https://medlineplus.gov/) (<https://medlineplus.gov/>) related topics:

[Cancer](https://medlineplus.gov/cancer.html) (<https://medlineplus.gov/cancer.html>), [Cancer](#)

[Immunotherapy](https://medlineplus.gov/cancerimmunotherapy.html) (<https://medlineplus.gov/cancerimmunotherapy.html>).

[FDA Drug and Device Resources](https://clinicaltrials.gov/fda-links) (<https://clinicaltrials.gov/fda-links>)

Contacts and Locations


This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the [Contacts and Locations section in How to Read a Study Record](https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations) (<https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations>).


This study has 9 locations

United States

California Locations

 **San Francisco, California, United States, 94115**
UCSF Helen Diller Family
Comprehensive Cancer Center


Colorado Locations

 **Aurora, Colorado, United States, 80045**
University of Colorado, Denver-Aurora


Georgia Locations

 **Atlanta, Georgia, United States, 30322**
Emory University

Massachusetts Locations

 **Boston, Massachusetts, United States, 02115**
Dana-Farber Cancer Institute

Michigan Locations

 **Detroit, Michigan, United States, 48201**
Karmanos Cancer institute

New York Locations

 **Buffalo, New York, United States,**
14263

Roswell Park Cancer Institute

 **New York, New York, United States,**
10021

Memorial Sloan Kettering Cancer Center

North Carolina Locations

 **Chapel Hill, North Carolina, United States, 27599**

University of North Carolina, Chapel Hill

Canada

Alberta Locations

 **Edmonton, Alberta, Canada, T6G 1Z2**

Cross Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called [eligibility criteria](#). Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read [Learn About Studies \(https://clinicaltrials.gov/study-basics/learn-about-studies\)](https://clinicaltrials.gov/study-basics/learn-about-studies).

Eligibility Criteria

Description

Inclusion Criteria: (For Dose Escalation and Dose Expansion)

- Subjects must have a tumor positive for Nectin-4 expression (as measured by

Ages Eligible for Study

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study

All

No

- central laboratory using primary or metastatic tumor tissue
- Histologically confirmed malignant solid tumors (excluding sarcoma) that have failed all FDA approved therapies indicated for the type of metastatic cancer and line of therapy or for which they were not a candidate to receive treatment

 - Measurable disease according to RECIST criteria (version 1.1) (Eisenhauer, et. al.) defined as tumor lesions that are accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of:
 - 10mm by CT scan (CT scan slice thickness no greater than 5mm
 - 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as nonmeasurable
 - 20 mm by chest X-ray
 - ≥ 15 mm in short axis for lymph nodes when

assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm)

Note: bone lesions, ascites, and pleural effusions are not considered measurable lesions

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Negative pregnancy test (women of childbearing potential)
- Hematologic function, as follows:
 - a. Absolute neutrophil count (ANC) $\geq 1.0 \times 10^9$ /L
 - b. Platelet count $\geq 100 \times 10^9$ /L
 - c. Hemoglobin ≥ 8.5 g/dL
- Renal function, as follows:
serum creatinine ≤ 2.0 mg/dL,
or measured 24 hour creatinine clearance of ≥ 45 mL/min
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Serum albumin > 2.5 g/dL
- Aspartate aminotransferase (AST) ≤ 1.5 x ULN
- Alanine aminotransferase (ALT) ≤ 1.5 x ULN
- Gamma GT ≤ 1.5 ULN
- International normalized ratio

(INR) < 1.5 (or ≤ 3 if on warfarin or other medications for therapeutic anticoagulation)

- Women and men of childbearing potential must be advised and agree to practice effective methods of contraception during the course of the study

Inclusion Criteria for Dose Expansion Only:

In addition to the inclusion criteria listed above, the following criteria will also be required for each expansion cohort:

Expansion Cohort 1: Breast Cancer

- Subjects with Histologically or cytologically diagnosed metastatic breast cancer

Expansion Cohort 2: Bladder Cancer

- Histologically or cytologically confirmed bladder cancer with visceral metastases

Expansion Cohort 3: Lung plus other solid tumor cancer

- Histologically or cytologically confirmed metastatic non-small cell lung cancer (NSCLC) or any other solid tumor cancer

Exclusion Criteria:

- Preexisting neuropathy Grade \geq 3 or motor neuropathy Grade \geq 2
- Uncontrolled brain or epidural spinal metastases
- Use of any investigational drug within 14 days or 5 half-lives prior to first dose of study drug
- Any anticancer therapy including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer within 28 days prior to first dose of study drug
- Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of the first dose of study drug, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication
- Known HIV or AIDS
- Decompensated liver disease as evidenced by clinically significant ascites refractory to diuretic therapy, hepatic

encephalopathy, or
coagulopathy

- History of thromboembolic events and bleeding disorders ≤ 3 months (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to first dose of study drug
- Major surgery within 28 days prior to first dose of study drug
- Active infection requiring treatment ≤ 7 days prior to first dose of study drug
- Anti-androgen therapy initiated within 28 days of enrollment (for prostate cancer patients only)
- Positive Hepatitis B surface antigen test
- Positive Hepatitis C antibody test

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose ⓘ : Treatment

Allocation ⓘ : Non-Randomized

Interventional Model ⓘ : Single Group Assignment

Masking ⓘ : None (Open Label)

Arms and Interventions

Participant Group/Arm ⓘ	Intervention/Treatment ⓘ
Experimental: AGS-22M6E-11-1 Dose Level 1	Drug: AGS-22M6E <ul style="list-style-type: none">• IV Infusion
Experimental: AGS-22M6E-11-1 Dose Level 2	Drug: AGS-22M6E <ul style="list-style-type: none">• IV Infusion
Experimental: AGS-22M6E-11-1 Dose Level 3	Drug: AGS-22M6E <ul style="list-style-type: none">• IV Infusion
Experimental: AGS-22M6E-11-1 Dose Level 4	Drug: AGS-22M6E <ul style="list-style-type: none">• IV Infusion
Experimental: AGS-22M6E-11-1 Dose Level 5	Drug: AGS-22M6E <ul style="list-style-type: none">• IV Infusion

Experimental: AGS-22M6E-11-1 Dose Level 6	Drug: AGS-22M6E <ul style="list-style-type: none"> • IV Infusion
Experimental: ASG-22CE Expansion Cohort 1 Breast Cancer	Drug: ASG-22CE <ul style="list-style-type: none"> • IV Infusion
Experimental: ASG-22CE Expansion Cohort 2 Bladder Cancer	Drug: ASG-22CE <ul style="list-style-type: none"> • IV Infusion
Experimental: ASG-22CE Expansion Cohort 3 Lung plus other solid tumor cancers	Drug: ASG-22CE <ul style="list-style-type: none"> • IV Infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events		Up to 28 days after the last dose of study drug
Composite of Pharmacokinetics: Ceoi or Cmax, Ctough, Tmax, AUC0-21, t½, CL, Vss	Concentration at the end of infusion (Ceoi) or Cmax, trough concentration (Ctough), Tmax, partial AUC after first dose (AUC0-21), terminal or apparent terminal half-life (t1/2), systemic clearance (CL), volume of distribution at steady state (Vss)	Up to 28 days after the last dose of study drug

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of anti-drug antibody formation		Up to 28 days after the last dose of study drug
Objective tumor response rate	Incidence of a tumor response is defined as a complete or partial response per Response Criteria for Solid Tumors (RECIST version 1.1)	Every 8 weeks (\pm 14 days)
Disease Control Rate		Every 8 weeks (\pm 14 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Astellas Pharma Inc

Collaborators

- Agensys, Inc.
- Seagen Inc.

Investigators

- Study Director: Medical Monitor, Agensys, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

2011-07-29

First Submitted that Met QC Criteria

2011-08-02

First Posted (Estimated)

2011-08-04

Study Record Updates

Last Update Submitted that Met QC Criteria

2024-03-11

Last Update Posted

2024-03-12

Last Verified

2024-02

More Information

Terms related to this study

Keywords Provided by Astellas Pharma Inc

Nectin 4 protein, humans
Cancer
Pharmacokinetics of AGS-22M6E
Pharmacokinetics of ASG-22CE
Safety
Clinical Trial, Phase 1
ASG-22ME
AGS-22M6E
ASG-22CE
ASG-22C3

Additional Relevant MeSH Terms

Neoplasms
enfortumab vedotin

Drug and device information, study documents, and helpful links

Helpful Links Provided by Astellas Pharma Inc

[Link to results and other applicable study documents on the Astellas Clinical Trials website](https://www.clinicaltrials.astellas.com/study/AGS-22M6E-11-1/) (<https://www.clinicaltrials.astellas.com/study/AGS-22M6E-11-1/>).

[Link to plain language summary of the study on the Trial Results Summaries website](https://www.trialssummaries.com/Study/StudyDetails?id=14368&tenant=MT_AST_9011) (https://www.trialssummaries.com/Study/StudyDetails?id=14368&tenant=MT_AST_9011).